Tabula Rasa Healthcare Inc (TRHC) Q2 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Operator
Good day, and thank you for standing by. Welcome to the Q1 2021 Tabula Rasa HealthCare, Inc. Earnings Conference Call. [Operator Instructions] So I would now like to hand the conference over to your speaker today, Kevin Dill, Corporate Counsel. Please go ahead.
Kevin J. Dill
General Counsel
Thank you, and good morning. I m Kevin Dill, Corporate Counsel for Tabula Rasa HealthCare. The company intends to avail itself of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain statements made during this call will be forward-looking statements within the meaning of that law. These forward-looking statements are subject to risks, uncertainties and other factors that could cause Tabula Rasa HealthCare s actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties include the developing nature of the market for technology-enabled healthcare products and services and po
MOORESTOWN, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE)
Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), today announced CEO, Chairman and Founder, Calvin H. Knowlton, Ph.D.; Co-Founder, President, Chief Marketing and Business Development Officer, Orsula V. Knowlton, PharmD; Chief Sales Officer, Kevin Boesen; and Chief Financial Officer, Brian W. Adams, will participate in the 39
th Annual J.P. Morgan Healthcare Conference to be held virtually January 11-14, 2021.
The TRHC presentation is scheduled for Thursday, January 14, 2021 at 4:30 p.m. EST. An audio replay of the presentation will be available at https://ir.tabularasahealthcare.com/.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) provides patient medication safety solutions empowering pharmacists and prescribers to optimize medication regimens and reduce medication-related risk, specifically targeting adverse drug events. Utilizing its proprietary medication decision science technology, MedWise™, TRHC improves